Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | LGMN | Q99538 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022889 | 0.85 | LGMN (0.54) | CA2CA5ACASP3LGMNCTSL | |
| SCHEMBL4016717 | 0.84 | CASP3 (0.51) | CA2CA5ACASP3LGMNCA1 | |
| SCHEMBL4019023 | 0.84 | CASP3 (0.50) | CA2CA5ACASP3LGMNCA1 | |
| SCHEMBL4020927 | 0.81 | CASP3 (0.48) | CA2CA5ACASP3LGMNCA1 | |
| SCHEMBL4015018 | 0.81 | CASP3 (0.55) | CA2CA5ACASP3CTSL | |
| SCHEMBL4018823 | 0.79 | CCR1 (0.47) | CA2CA5ACASP3LGMNCA1 | |
| SCHEMBL16421523 | 0.78 | LGMN (0.67) | LGMNCTSLCTSSCTSBCTSK | |
| SCHEMBL4022177 | 0.77 | CASP3 (0.54) | CASP3LGMNCTSLCTSBCTSK | |
| SCHEMBL4013593 | 0.77 | CASP3 (0.55) | CASP3LGMNCTSLCTSBCTSK | |
| SCHEMBL6427219 | 0.76 | CA2 (0.61) | CA2CA5ACA1SIRT2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482379-B2 | Propenoyl hydrazides | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050256058-A1 | Propenoyl hydrazides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256058-A1 | Propenoyl hydrazides | DNPEP, HPN, PREP | CA2 1120/4885CA5A 478/4885CASP3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.